Add Content...

Publications & Patents

Products Under Development * Publications & Patents


OncoQuest Issued Immunotherapy Patents

Patent Number



US 6,716,966

US 7,147,850

Therapeutic Binding Agents Against MUC-1 Antigen and Methods



US 7,361,346

US 7,318,921

Therapeutic Compositions that Produce an Immune Response



US 6,241,985

Method and Composition for Reconforming Multi-Epitopic Antigens to Initiate an Immune Response


US 6,881,405

US 7,579,445

Reagents and Methods for Inducing an Immune Response to Prostate Specific Antigen



US 6,689,355 Therapeutic Method and Composition Utilizing Antigen-Antibody Complexation and Presentation by Dendritic Cells 10-Feb-2004
US 8,038,994 Combination Therapy for Treating Disease 18-Oct-2011
EU 1,357,944 Perylenequinones for Use with Immunotherapy Agents 13-Jun-2007
US 8,697,079 IgE Antibodies for the Treatment of Cancer 15-Apr-2014
US 8,945,566 Methods for Improving the Bioacivity of Therapeutic IgE Antibodies for the TReatment of Disease 3-Feb-2015


OncoQuest Publications:

  1. Braly P, Nicodemus CF, Chu C et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother. 2009 Jan;32(1):54-65
  2. Jonathan Berek, Peyton Taylor, William McGuire, L. Mary Smith, Birgit Schultes, and Christopher F. Nicodemus. Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. J Clin Oncol 2009; 27:418-425
  3. Alan N. Gordon, Birgit C. Schultes, Holly Gallion, Robert Edwards, Theresa L. Whiteside, Jennifer M. Cermak and Christopher F. Nicodemus. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecologic Oncology 94 (2004) 340–351
  4. Jonathan S. Berek, Peyton T. Taylor, Alan Gordon, Mary J. Cunningham, Neil Finkler, James Orr, Jr, Saul Rivkin, Birgit C. Schultes, Theresa L. Whiteside, Christopher F. Nicodemus. Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer. J Clin Oncol 2004; 22:3507-3516
  5. Berek J.S. Immunotherapy of Ovarian cancer with antibodies: a focus on Oregovomab Expert Opinion of Biological Therapy 2004; 4:1159-1165
  6. Birgit C. Schultes and Christopher F. Nicodemus. Using Antibodies in Tumour Immunotherapy. Opinion of Biological Therapy 2004; 4:1265-1284
  7. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34.
  8. Nicodemus CF, Wang L, Lucas J, et al. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol 2010; 202:608.e1-8.
  9. Qi W, Schultes BC, Liu D, Kuzma M, Decker W, Madiyalakan R. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics 20(5-6):313-24, 2001.
  10. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 15(12):1825-33, 2004
  11. Tracy R. Daniels, Richard K. Leuchter, Rafaela Quintero, Gustavo Helguera, Jose´ A. Rodrı´guez, Otoniel Martı´nez-Maza, Birgit C. Schultes, Christopher F. Nicodemus, Manuel L. Penichet. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother (2012) 61:991–1003
  12. Pearline Zhaoying Teo, Paul J. Utz, Joseph A. Mollick. Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol Immunother (2012)61:2295-309
  13. Nicodemus CF. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy 2015;7(8):923-39
  14. Tracy R Daniels-Wells, Gustavo Helguera, Richard K Leuchter, Rafaela Quintero,Maggie Kozman, José A Rodríguez, Elizabeth Ortiz-Sánchez, Otoniel Martínez-Maza, Birgit C Schultes, Christopher F Nicodemus and Manuel L Penichet. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer. 2013; 13: 195